HOME >> MEDICINE >> NEWS
Mouse study gives new view of anthrax toxin

A large-scale study of anthrax in mice has yielded new information about immune system response to anthrax bacteria, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health. The discovery that toxins released by the bacteria do not behave as previously believed should redirect approaches to anthrax drug design, notes NIAID Senior Investigator Stephen Leppla, Ph.D., whose research is published in today's issue of the Journal of Clinical Investigation.

In the new study, Dr. Leppla and his colleagues injected hundreds of inbred mice with anthrax lethal toxin (LT), and then took precisely timed measurements to determine how various organs and immune system processes responded. For example, they measured levels of chemicals called cytokines, which are released by immune system cells after a bacterial invasion. Dr. Leppla and his colleagues found no evidence of a persistent increase in cytokines, or of a link between cytokine increase and anthrax LT effects, contradicting earlier beliefs.

The evidence suggests that current efforts to design cytokine-suppressing drugs to treat lethal toxin-mediated events in late stages of anthrax may be misguided. "Finding effective therapies for diseases such as inhalational anthrax depends on our ability to connect basic research with clinicians' needs. This research is a perfect example of such translational research," says NIAID Director Anthony S. Fauci, M.D.

"Science has had a good understanding of anthrax toxins at molecular and subcellular levels," says Dr. Leppla. "What has been lacking is a picture of the much more complex effects of toxins on tissues and animal models. Ours is one of the first comprehensive studies to critically examine what is actually happening at these higher levels of complexity."

In a natural infection, inhalational anthrax begins after anthrax bacteria spores enter the body, germinate and rel
'"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
2-Sep-2003


Page: 1 2

Related medicine news :

1. Mouse model reveals potential way to reduce cardiac deaths in kidney patients
2. Mouse gene shows new mechanism behind cardiac infarction in man
3. Mouse model gives insight to human hair loss
4. Mouse study: Signal overload in Alzheimer brains
5. Mouse shows how Rituximab removes human B cells
6. Mouse study could aid vaccine designers
7. Mouse model mimics real-world plague infection
8. Mouse antibodies thwart SARS virus
9. Mouse model of neuromuscular disease identifies key player in motor neuron death
10. Mouse studies reveal immune mechanism involved in bone loss caused by estrogen deficiency
11. Mouse provides clues about chronic pain

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Mouse study gives new view anthrax toxin

(Date:5/18/2013)... Orlando, FL (May 18, 2013) There are ... procedures commonly used to diagnose or treat gastrointestinal ... Week (DDW). , A study by New ... that more objective testing may substantially reduce the ... (GERD). Although GERD is believed to affect nearly ...
(Date:5/18/2013)... Utah (PRWEB) May 18, 2013 ... on insurance agents’ role in Marketplaces . ... to traditional employer sponsored health benefits, is the ... and health reimbursement arrangements . , ... Health and Human Services (HHS) recently released a ...
(Date:5/18/2013)... 2013 After working diligently for months and ... formally announced the integration of the fitment specs for the ... set to stun the automobile market with its extraordinary features ... is marked as the latest entry in the size ... up for the year 2013. , Aptly suiting its ...
(Date:5/18/2013)... AL (PRWEB) May 18, 2013 Although ... malignant tumors, the association between obesity and esophageal adenocarcinoma, ... for other obesity-related tumors. As reported on ... people are almost twice as likely as those of ... Although the relationship between obesity and esophageal cancer is ...
(Date:5/18/2013)... Houston, TX (PRWEB) May 18, 2013 Show ... many years of various different training systems that is all ... possible has caught the attention of http://ShowAndGoTrainingReview.com ’s ... Go Training is a unique “four phase system” designed ... the minimum amount of time spent working out in the ...
Breaking Medicine News(10 mins):Health News:New research identifies practice changes to improve value and quality of GI procedures 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3Health News:Show And Go Training: Review Examining Eric Cressy's Workout Program Revealed 2
(Date:5/17/2013)... JERUSALEM , May 17, 2013 ... a developer of oral drug delivery systems, announced today ... has cleared the Company,s Investigational New Drug application(IND) for ... very pleased to have the FDA clearance to proceed," ... Oramed. "The upcoming trial is a major milestone for ...
(Date:5/17/2013)... , May 17, 2013  Boston Scientific Corporation ... at the annual EuroPCR Scientific Program May 21-24 in ... pleased to present a particularly rich and diversified set ... Keith Dawkins , M.D., global chief medical officer, ... will be presented, including the NG PROMUS trial, which ...
(Date:5/16/2013)... MECHELEN, Belgium , May 17, 2013 ... ABBV ) announced today an extension of ... Galapagos will fund and complete a Phase 2 program ... progression into Phase 3.  Upon successful completion of the ... $50 million.  The terms of the collaboration extension are ...
Breaking Medicine Technology:Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6
Cached News: